- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02254070
Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment
30 september 2014 bijgewerkt door: Boehringer Ingelheim
Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of 1.0 mg of BIBT 986 BS Given as a Single Dose Infusion Over 30 Minutes in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment in an Open, Group Comparison Design
To assess the influence of different degrees of renal impairment on safety, tolerability, pharmacodynamics and pharmacokinetics of 1.0 mg of BIBT 986 BS given as a single dose infusion over 30 minutes in comparison to a normal renal function
Studie Overzicht
Studietype
Ingrijpend
Inschrijving (Werkelijk)
23
Fase
- Fase 1
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar tot 75 jaar (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Ja
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Healthy male or female subjects determined by results of screening with a creatinine clearance >80 mL/min (Group 1)
Renally impaired male or female subjects determined by results of screening with the following creatinine clearance results:
- creatinine clearance 51-80 mL/min (Group 2)
- creatinine clearance 31-50 mL/min (Group 3)
- creatinine clearance ≤ 30 mL/min (Group 4)
- subjects requiring hemodialysis (Group 5)
- Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
- Age >=18 and <=75 years
- BMI >=18.5 and <=29.9 kg/m2 for Groups 1+2
- BMI >=18.5 and <=32 kg/m2 for Groups 3, 4 and 5
Exclusion Criteria:
- Any finding of the medical examination (including blood pressure, pulse rate, and electrocardiogram) deviating from normal and of clinical relevance
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders
- Surgery of gastrointestinal tract (except appendectomy)
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- Relevant history of orthostatic hypotension, fainting spells or blackouts
- Abnormal PT, TT, aPTT (must be within the normal range after no more than one repeated test), thrombocytes < 150000/μl (two repeats of the first test)
- Evidence of haematuria either macroscopically detectable or microscopic on urinalysis (normal microscopic results after no ore than one repeated test)
- Evidence of blood dyscrasia, haemorrhagic diathesis, severe thrombocytopenia, cerebrovascular haemorrhage, bleeding tendencies associated with active ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary tract or any disease or condition with haemorrhagic tendencies (e.g. cerebral aneurysm, dissecting aorta, CNS trauma, retinopathy, nephrolithiasis)
- Recent or contemplated diagnostic or therapeutic procedures with potential for uncontrollable bleeding (e.g. spinal puncture, lumbar block anaesthesia, surgery of central nervous system (CNS) or eye or surgery resulting in large open surfaces) within 14 days before or after drug administration of this clinical trial
- Occult blood in 1 of 3 subsequent faecal samples collected for the pre-study examination
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- For women with childbearing potential: no reliable contraception (accepted methods are intra uterine device, hormonal contraceptives, bilateral tubal ligation, hysterectomy, condoms) or pregnancy (known or detected by a positive pregnancy test) or breast feeding period
- Intake of drugs with a long half-life (> 24 hours) (< 1 month prior to administration or during the trial)
- Use of any drugs, within 14 days prior to administration or during the trial
- Participation in another trial with an investigational drug (< 2 months prior to administration or during trial)
- Smoker (> 10 cigarettes or >3 cigars or >3 pipes/day)
- Alcohol abuse (> 60 g/day)
- Drug abuse
- Blood donation or loss > 400 ml, < 1 month prior to administration or during the trial
- Excessive physical activities < 5 days prior to administration of study drug or during trial
- Clinically relevant laboratory abnormalities
- Veins unsuited for i.v. puncture and administration of prolonged infusions on either arm (e.g. veins which are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture, etc.)
Renally impaired subjects (Group 2, 3, 4 and 5) who meet any of the following criteria will not be entered into this trial:
- Moderate and severe concurrent liver function impairment (e.g., due to hepatorenal syndrome)
- Gastrointestinal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders
- Surgery of gastrointestinal tract (except appendectomy)
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- Relevant history of orthostatic hypotension, fainting spells or blackouts
- Abnormal values for PT, TT, aPTT and thrombocytes considered by the investigator or one of the co-investigators to be clinically relevant
- Hemoglobin concentration <9 mg/dl
- Evidence of blood dyscrasia, haemorrhagic diathesis, severe thrombocytopenia, cerebrovascular haemorrhage, bleeding tendencies associated with active ulceration or overt bleeding of gastrointestinal, respiratory or genitourinary tract or any disease or condition with haemorrhagic tendencies (e.g. cerebral aneurysm, dissecting aorta,CNS trauma, retinopathy, nephrolithiasis) considered by the investigator or one of the co-investigators to be clinically relevant
- Recent or contemplated diagnostic or therapeutic procedures with potential for uncontrollable bleeding (e.g. spinal puncture, lumbar block anaesthesia, surgery of CNS or eye or surgery resulting in large open surfaces) within 14 days before or after drug administration of this clinical trial
- Occult blood in 1 of 3 subsequent faecal samples collected for the pre-study examination
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- For women with childbearing potential: no reliable contraception (accepted methods are intra uterine device, hormonal contraceptives, bilateral tubal ligation, hysterectomy, condoms) or pregnancy (known or detected by a positive pregnancy test) or breast feeding period
- Faecal occult blood (FOB) in 1 of 3 subsequent samples collected for the pre-study examination
- Use of any drugs which have an influence on the blood clotting within 14 days prior to administration or during the trial (except heparin for hemodialysis patients)
- Participation in another trial with an investigational drug (< 2 months prior to administration or during trial)
- Smoker (> 10 cigarettes or >3 cigars or >3 pipes/day)
- Alcohol abuse (> 60 g/day)
- Drug abuse
- Blood donation or loss > 400 ml, < 1 month prior to administration or during the trial
- Excessive physical activities < 5 days prior to administration of study drug or during trial
- Clinically relevant laboratory abnormalities
- Veins unsuited for i.v. puncture and administration of prolonged infusions on either arm (e.g. veins which are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture, etc.)
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: BIBT 986 BS
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Eindsnelheidsconstante van de analyt in plasma (λz)
Tijdsspanne: Tot 48 uur na toediening van het geneesmiddel
|
Tot 48 uur na toediening van het geneesmiddel
|
|
Maximaal gemeten concentratie van de analyt in plasma (Cmax)
Tijdsspanne: Tot 48 uur na toediening van het geneesmiddel
|
Tot 48 uur na toediening van het geneesmiddel
|
|
Terminale halfwaardetijd van de analyt in plasma (t1/2)
Tijdsspanne: Tot 48 uur na toediening van het geneesmiddel
|
Tot 48 uur na toediening van het geneesmiddel
|
|
Time to reach the maximum concentration of the analyte in plasma (tmax)
Tijdsspanne: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
Total area under the plasma drug concentration-time curve from time zero to infinity (AUC0-∞)
Tijdsspanne: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
Area under the concentration-time curve of the analyte in plasma from zero time to the time of the last quantifiable drug concentration (AUC0-tz)
Tijdsspanne: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
Mean residence time of the analyte in the body after intravenous infusion (MRTinf)
Tijdsspanne: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
Total clearance of the analyte from plasma following intravascular administration (CL)
Tijdsspanne: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
Apparent volume of distribution at steady state following an intravascular dose (Vss)
Tijdsspanne: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
Apparent volume of distribution during the terminal phase λz following an intravascular dose (Vz)
Tijdsspanne: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
Amount of drug excreted in the urine (Ae)
Tijdsspanne: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
Change in activated partial thromboplastin time (aPTT)
Tijdsspanne: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
Change in ecarin clotting time (ECT)
Tijdsspanne: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
Change in International Normalized Ratio (INR)
Tijdsspanne: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
Change in thrombin time (TT)
Tijdsspanne: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
Plasma concentration of the analyte at the end of the intravenous infusion (CT)
Tijdsspanne: 29 minutes after drug administration
|
29 minutes after drug administration
|
|
Number of participants with clinically significant changes in vital signs
Tijdsspanne: Up to 3 days after drug administration
|
Blood pressure and pulse rate
|
Up to 3 days after drug administration
|
Number of participants with clinically significant changes in ECG (electrocardiogram)
Tijdsspanne: Up to 3 days after drug administration
|
Up to 3 days after drug administration
|
|
Number of participants with abnormal changes in clinical laboratory parameters
Tijdsspanne: Up to 3 days after drug administration
|
Up to 3 days after drug administration
|
|
Number of participants with adverse events
Tijdsspanne: Up to 3 days after drug administration
|
Up to 3 days after drug administration
|
|
Change in prothrombin time (PT)
Tijdsspanne: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
partial area under the concentration time curve (from time 0 to last sampling time preceding hemodialysis in any of the patients) (AUCt1-t2)
Tijdsspanne: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
fraction of administered drug excreted unchanged in urine over the respective time interval (fe)
Tijdsspanne: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
|
Renal clearance of the analyte from plasma following intravascular administration (CLR)
Tijdsspanne: Up to 48 hours after drug administration
|
Up to 48 hours after drug administration
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Nuttige links
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start
1 juni 2003
Primaire voltooiing (Werkelijk)
1 augustus 2004
Studieregistratiedata
Eerst ingediend
30 september 2014
Eerst ingediend dat voldeed aan de QC-criteria
30 september 2014
Eerst geplaatst (Schatting)
1 oktober 2014
Updates van studierecords
Laatste update geplaatst (Schatting)
1 oktober 2014
Laatste update ingediend die voldeed aan QC-criteria
30 september 2014
Laatst geverifieerd
1 september 2014
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 1192.12
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Gezond
-
University of LeicesterNational Institute for Health Research, United KingdomVoltooidPatiënten met hartfalen en behouden ejectiefractie - HFpEF | Patiënten met hartfalen met verminderde ejectiefractie - HFrEF | Healthy Controls Group - Leeftijd en geslacht afgestemd
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesBeëindigdZiekte van Parkinson | Healthy Controls Group - Leeftijd en geslacht afgestemdFrankrijk
Klinische onderzoeken op BIBT 986 BS
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooid
-
SunovionPPD; ICON Clinical Research; Covance; Dainippon Sumitomo Pharma America; ClinPhone,...VoltooidOveractieve blaassyndroom (OABS)Frankrijk, Verenigd Koninkrijk, Verenigde Staten, Estland, Duitsland, Letland, Litouwen, Polen, Spanje
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooid
-
Boehringer IngelheimVoltooidLongziekte, chronisch obstructief
-
National Defense Medical Center, TaiwanMinistry of Science and Technology, TaiwanVoltooidTe vroeg geboren baby's | Ouder-kindrelaties | Vroege interventies